Malagueule's Lounge

[malagueule]

NEWC to produce Infomercials!!

BARRANQUILLA, Colombia, October 21, 2016 /PRNewswire/ --

New Colombia Resources, Inc. (NEWC) ("New Colombia or the Company"), a U.S. listed Colombian company with natural resource assets in Colombia, is pleased to announce plans to produce several infomercials targeting the U.S. Hispanic and Latin American Markets. The Company had previously engaged top infomercial producer to conduct a market survey of pain products vs. beauty products.

Doral Studios Inc. d/b/a RC Television Production has been producing English and Spanish speaking infomercials and music videos for over 15 years. They have a state of the art production studio in Doral, FL where they have produced the most successful Spanish language infomercials on the air in the U.S. and Latin America. RC Television handles every aspect of an infomercial including: concept, logo, animation, graphics, passive and aggressive CTA (Call to Action), and high definition production. They work with focus groups to determine the direction of the product or idea.

Rafael Campo, Owner of Doral Studios, has long standing relationships with the biggest Spanish language broadcasters in the world and works with telemarketing associates to handle incoming calls. New Colombia Resources' President, John Campo, and Rafael Campo are related. To view Doral Studios demos visit

Doral Studios conducted a survey to determine what type of cannabis based product would be most accepted by their target audience. The population subject of the study included male and female professionals, makeup artists, personal trainers, corporate executives, students, housewives, and others. The age brackets were broken down every ten years, except for the first segment that was from age 25 to 40. The results of the survey will be posted next week.

Once Doral Studios and the Company determine which product they feel will have the best results, New Colombia Resources will work with their scientific advisor, Dr. Robert Melamede PhD, President Emeritus of Cannabis Science Inc. (CBIS), a world-renowned expert on the body's Endocannabinoid System, and other credible doctors to help explain to the Hispanic and Latin American why cannabis based products work.

According to published reports, the U.S. Hispanic buying power is over $ 1.5 Trillion and spends the most on consumer goods over other multi-cultural segments. "We feel our target audience will accept our "Made in Colombia" products over other cannabis products of inferior quality," stated John Campo, President of New Colombia Resources, Inc.

Products the company plans to advertise to the Hispanic market include their all natural pain relief cream http://www.sannabis.co/_p/prd2/2838276511/product/pomada-caliente made with the following all natural active ingredients...

Bees Wax
Eucalyptus
Pine
Nettle
Castor Bean
Tabaco
Cannabis Sativa Flower (5 grams)



Additionally, New Colombia Resources will give updates on their cannabis based Orphan Drug Designation application with the FDA as they develop. Other companies with orphan drug business plans include OWC Pharmaceutical Research Corp. (OWCP).

To view or purchase cannabis based products from the Company's medical marijuana joint venture in Colombia, Sannabis, visit http://www.sannabis.co. Follow Sannabis on Facebook for photos and testimonials at https://www.facebook.com/sannabis.cannamedicinal

About New Colombia Resources, Inc.

New Colombia Resources, Inc. is focused on the acquisition and development of high-quality metallurgical coal properties and other available resources in the Republic of Colombia. They expect to have several revenues producing businesses including; metallurgical coal mining and rock quarry aggregates for domestic Colombian highway and railroad building projects, and medical marijuana products. The Company owns 100% of La Tabaquera metallurgical coal mine in Colombia with an estimated 15- 17 million tonnes of reserves. They have another pending acquisition for 390 ha and a solicitation contract for 184 ha metallurgical coal concession. New Colombia Resources holds a significant position in Sannabis SAS which legally produces medical marijuana products in the Republic of Colombia, visit http://www.sannabis.co. For more information on the Company visit http://www.newcolombiaresources.com.

Link: http://finance.yahoo.com/news/colombia-resources-inc-produce-infomercials-161500145.html

[malagueule]

UpdateDD on growth and value of OWCP

OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!

OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.

Big Money to be made here.

Multiple myeloma - orphan status designation possible - $7.3 billion in 2014 to $8.9 billion by 2021
Psoriasis - marketing of a cannabinoid-based topical cream - $6.6 billion in 2014 to over $13.3 billion by 2024
Fibromyalgia - orphan status designation possible - $1.8 billion in 2013 to $1.9 billion by 2023
Post-Traumatic Stress Disorder ( PTSD ) - annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion
Source links below.


Multiple myeloma - In preliminary studies, OWCP's in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.

Psoriasis - OWCP completed development of a Topical Cream infused with Cannabis oil extracts to be studied for Psoriasis skin disease. OWCP has started the final phase of Safety testing protocol was designed to corroborate that the cream is safe for application to the skin. OWCP is also preparing to initiate in parallel Efficacy Testing using MatTek Corporation patented EpiDerm™ system, an in-vitro testing technology for dermal toxicologists. This protocol will seek to prove the effectiveness of the formulation in treating psoriasis on human skin tissue.

Post-Traumatic Stress Disorder ( PTSD ) - An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas. At present,OWCP is negotiating with two other Israeli leading medical centers for the collaboration in the research of migraine and PTSD (post-traumatic stress disorder). The Company expects these agreements to be finalized during the fourth quarter of 2015.




Links to market value of treatment:

The global multiple myeloma treatment market value link http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi-0
The psoriasis market value link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/psoriasis-market-will-more-than-double-to-133-billion-by-2024-as-drugs-greatly-improve
The treatment market value for fibromyalgia link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/fibromyalgia-treatment-market-value-will-crawl-to-19-billion-by-2023-says-globaldata
anxiety disorders annual cost to society link http://www.ptsdunited.org/ptsd-statistics-2/
-----
Link to in-vitro data and interview http://www.baystreet.ca/viewarticle.aspx?id=437873
Link to final cream phase http://www.cnbc.com/2016/10/11/pr-newswire-owc-pharmaceutical-research-corp-to-initiate-efficacy-testing-on-its-cannabinoid-infused-cream-for-treatment-of-psoriasis.html

[malagueule]

UpdateDD on growth and value of OWCP

OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!

OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.

Big Money to be made here.

Multiple myeloma - orphan status designation possible - $7.3 billion in 2014 to $8.9 billion by 2021
Psoriasis - marketing of a cannabinoid-based topical cream - $6.6 billion in 2014 to over $13.3 billion by 2024
Fibromyalgia - orphan status designation possible - $1.8 billion in 2013 to $1.9 billion by 2023
Post-Traumatic Stress Disorder ( PTSD ) - annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion
Source links below.


Multiple myeloma - In preliminary studies, OWCP's in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.

Psoriasis - OWCP completed development of a Topical Cream infused with Cannabis oil extracts to be studied for Psoriasis skin disease. OWCP has started the final phase for testing the efficacy of its own developed topical crème compound for the treatment of psoriasis and related skin conditions.

Post-Traumatic Stress Disorder ( PTSD ) - An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas. At present,OWCP is negotiating with two other Israeli leading medical centers for the collaboration in the research of migraine and PTSD (post-traumatic stress disorder). The Company expects these agreements to be finalized during the fourth quarter of 2015.




Links to market value of treatment:

The global multiple myeloma treatment market value link http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi-0
The psoriasis market value link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/psoriasis-market-will-more-than-double-to-133-billion-by-2024-as-drugs-greatly-improve
The treatment market value for fibromyalgia link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/fibromyalgia-treatment-market-value-will-crawl-to-19-billion-by-2023-says-globaldata
anxiety disorders annual cost to society link http://www.ptsdunited.org/ptsd-statistics-2/
-----
Link to in-vitro data and interview http://www.baystreet.ca/viewarticle.aspx?id=437873

[malagueule]

OWCP has a Patent on Cannabis Condoms, Anyone remember how much pfizer went up with the blue pill?

NOVEL CONDOM COMPRISING CANNABIS DERIVED COMPOSITIONS FOR ENHANCEMENT OF SEXUAL PLEASURE AND DECREASE OF ERECTILE DYSFUNCTION SYMPTOMS

FIELD OF THE INVENTION

The present invention is in the field of contraceptive and prophylactic devices. More particularly, it pertains to providing condoms made of novel materials comprising cannabis or cannabis derived compositions for enhancement of sexual pleasure and decrease of erectile dysfunction symptoms, and to condoms additives (like lubricants) comprising cannabis or cannabis derived compositions for treatment of the same.

The present invention provides a biocompatible polymer or biocompatible material or composition for forming at least part of the structure of a condom useful for preventing STI's. The biocompatible polymer incorporates cannabis or cannabis derived compositions. The present invention also provides a biocompatible additive for condoms incorporating cannabis or cannabis derived compositions in a carrier or excipient. In addition, the biocompatible polymer or biocompatible additive incorporating cannabis or cannabis derived compositions enhances pleasure during the sexual act. Lastly, the biocompatible polymer or biocompatible additive incorporating cannabis or cannabis derived compositions can be used for the treatment of erectile dysfunction.

link https://www.google.com/patents/WO2016098112A1?cl=en&dq=inassignee:%22One+World+Cannabis+Ltd%22&hl=en&sa=X&ved=0ahUKEwjVyuzX5M_PAhWB6iYKHSDvACkQ6AEIHjAA

[malagueule]

UpdateDD on growth and value of OWCP

OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!

OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.

Big Money to be made here.

Multiple myeloma - orphan status designation possible - $7.3 billion in 2014 to $8.9 billion by 2021
Psoriasis - marketing of a cannabinoid-based topical cream - $6.6 billion in 2014 to over $13.3 billion by 2024
Fibromyalgia - orphan status designation possible - $1.8 billion in 2013 to $1.9 billion by 2023
Post-Traumatic Stress Disorder ( PTSD ) - annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion
Source links below.


Multiple myeloma - In preliminary studies, OWCP's in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.

Psoriasis - OWCP completed development of a Topical Cream infused with Cannabis oil extracts to be studied for Psoriasis skin disease. OWCP has finished the IRB (Institutional Review Board) protocol for Phase I equivalent, double blind, randomized and placebo-controlled study, which will be submitted for approval.

Post-Traumatic Stress Disorder ( PTSD ) - An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas. At present,OWCP is negotiating with two other Israeli leading medical centers for the collaboration in the research of migraine and PTSD (post-traumatic stress disorder). The Company expects these agreements to be finalized during the fourth quarter of 2015.




Links to market value of treatment:

The global multiple myeloma treatment market value link http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi-0
The psoriasis market value link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/psoriasis-market-will-more-than-double-to-133-billion-by-2024-as-drugs-greatly-improve
The treatment market value for fibromyalgia link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/fibromyalgia-treatment-market-value-will-crawl-to-19-billion-by-2023-says-globaldata
anxiety disorders annual cost to society link http://www.ptsdunited.org/ptsd-statistics-2/
-----
Link to in-vitro data and interview http://www.baystreet.ca/viewarticle.aspx?id=437873

[malagueule]

UpdateDD on growth and value of OWCP

OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!

OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.

Big Money to be made here.

Multiple myeloma - orphan status designation possible - $7.3 billion in 2014 to $8.9 billion by 2021
Psoriasis - marketing of a cannabinoid-based topical cream - $6.6 billion in 2014 to over $13.3 billion by 2024
Fibromyalgia - orphan status designation possible - $1.8 billion in 2013 to $1.9 billion by 2023
Post-Traumatic Stress Disorder ( PTSD ) - annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion
Source links below.


Multiple myeloma - In preliminary studies, OWCP's in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.

Psoriasis - OWCP completed development of a Topical Cream infused with Cannabis oil extracts to be studied for Psoriasis skin disease. OWCP has finished the IRB (Institutional Review Board) protocol for Phase I equivalent, double blind, randomized and placebo-controlled study, which will be submitted for approval.

Post-Traumatic Stress Disorder ( PTSD ) - An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas. At present,OWCP is negotiating with two other Israeli leading medical centers for the collaboration in the research of migraine and PTSD (post-traumatic stress disorder). The Company expects these agreements to be finalized during the fourth quarter of 2015.




Links to market value of treatment:

The global multiple myeloma treatment market value link http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi-0
The psoriasis market value link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/psoriasis-market-will-more-than-double-to-133-billion-by-2024-as-drugs-greatly-improve
The treatment market value for fibromyalgia link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/fibromyalgia-treatment-market-value-will-crawl-to-19-billion-by-2023-says-globaldata
anxiety disorders annual cost to society link http://www.ptsdunited.org/ptsd-statistics-2/
-----
Link to in-vitro data and interview http://www.baystreet.ca/viewarticle.aspx?id=437873

[malagueule]

DD on Future growth and value creation of this stock - Big Money to be made here.

OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!

OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.

Multiple myeloma - orphan status designation

NEW YORK (GBI Research) - The global multiple myeloma treatment market value will expand from $7.3 billion in 2014 to $8.9 billion by 2021, representing a moderate Compound Annual Growth Rate (CAGR) of 4.6%, says business intelligence provider GBI Research.
link http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi-0
-----
A form of bone marrow cancer that accounts for 2% of all cancer deaths. In preliminary studies, the Company demonstrated that some combinations of THC and CBD led to the eradication of 100% of myeloma cells in 60% of the cultured cells within 24 to 48 hours of exposure to the cannabinoid formulation. These early stage in-vitro results may be limited, but they demonstrate significant potential within the market.
Link http://www.baystreet.ca/viewarticle.aspx?id=437873

Psoriasis - marketing of a cannabinoid-based topical cream

The psoriasis market is set to rise from $6.6 billion in 2014 to over $13.3 billion by 2024 at a compound annual growth rate of 7.3%, according to research and consulting firm GlobalData.
link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/psoriasis-market-will-more-than-double-to-133-billion-by-2024-as-drugs-greatly-improve

fibromyalgia - orphan status designation

The treatment market value for fibromyalgia across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will expand from $1.8 billion in 2013 at a tepid Compound Annual Growth Rate (CAGR) of 0.72% to reach $1.9 billion by 2023, according to research and consulting firm GlobalData
link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/fibromyalgia-treatment-market-value-will-crawl-to-19-billion-by-2023-says-globaldata

post-traumatic stress disorder ( PTSD )

The annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion, often due to misdiagnosis and under treatment. This includes psychiatric and non-psychiatric medical treatment costs, indirect workplace costs, mortality costs, and prescription drug costs. An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas.
link http://www.ptsdunited.org/ptsd-statistics-2/

Technavio's analysts forecast the global PTSD therapeutics market to grow at a CAGR of 1.09% over the period 2014-2019.
link http://www.prnewswire.com/news-releases/global-post-traumatic-stress-disorder-therapeutics-market-2015-2019-300109175.html

[malagueule]

big money in owcp

OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!

OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.

Multiple myeloma

NEW YORK (GBI Research) - The global multiple myeloma treatment market value will expand from $7.3 billion in 2014 to $8.9 billion by 2021, representing a moderate Compound Annual Growth Rate (CAGR) of 4.6%, says business intelligence provider GBI Research.
link http://www.fiercepharma.com/marketing/global-multiple-myeloma-treatment-market-value-to-approach-9-billion-by-2021-says-gbi-0

Psoriasis

The psoriasis market is set to rise from $6.6 billion in 2014 to over $13.3 billion by 2024 at a compound annual growth rate of 7.3%, according to research and consulting firm GlobalData.
link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/psoriasis-market-will-more-than-double-to-133-billion-by-2024-as-drugs-greatly-improve

fibromyalgia

The treatment market value for fibromyalgia across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will expand from $1.8 billion in 2013 at a tepid Compound Annual Growth Rate (CAGR) of 0.72% to reach $1.9 billion by 2023, according to research and consulting firm GlobalData
link https://healthcare.globaldata.com/media-center/press-releases/pharmaceuticals/fibromyalgia-treatment-market-value-will-crawl-to-19-billion-by-2023-says-globaldata

post-traumatic stress disorder ( PTSD )

The annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion, often due to misdiagnosis and under treatment. This includes psychiatric and non-psychiatric medical treatment costs, indirect workplace costs, mortality costs, and prescription drug costs. An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas.
link http://www.ptsdunited.org/ptsd-statistics-2/

Technavio's analysts forecast the global PTSD therapeutics market to grow at a CAGR of 1.09% over the period 2014-2019.
link http://www.prnewswire.com/news-releases/global-post-traumatic-stress-disorder-therapeutics-market-2015-2019-300109175.html

[malagueule]

owcp Alerted @ 0.0093

[malagueule]

OWCP DD

Authorized Shares 500,000,000 a/o Sep 23, 2016
Outstanding Shares 96,799,955 a/o Sep 23, 2016

Company only has 2 notes net of $51,969K which are mostly converted the past month

See below NO MORE TOXICS OWCP got $300k NON INTEREST BEARING LOAN WITH NO CONVERSION RIGHTS TO FUND OPERATIONS


OWCP an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it signed an agreement for $300,000 with Medmar LLC ("Medmar").

According to the terms of the agreement:

The funds will be allocated to complete the development of the Company's proprietary psoriasis cream;

Medmar will have exclusive right to manufacture, produce, publicize, promote and market OWC's Licensed Products in any state in the U.S;

The loan is non-interest bearing and will be repaid from royalties generated by the sale of OWC licensed products.

More details:
Medmar has agreed to loan OCW Ltd a total of $300,000 (the “Loan”) on a non-interest bearing basis, with no conversion rights. Medmar will fund the Loan in six equal installments of $50,000 each, as follows: (i) 1st installment was released to OWC Ltd on September 22, 2016; (ii) 2nd installment on October 1, 2016; (iii) 3rd installment on November 1, 2016; (iv) 4th installment on December 1, 2016; (v) 5th installment on January 1, 2017; and (vi) 6th installment on February 1, 2017. The Loan, as noted above, bears no interest, is not convertible, is due in 36 months from the Effective Date, and repayment shall be made only by the set off of royalties payable by Medmar to OWC Ltd.

PR:https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-signs-120000921.html

8k: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11614519

!!OWC Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!

There are many different companies active in the medical marijuana industry, but few of them are conducting clinical research trials in accord with the Helsinki Committee Institutional Review Board protocols. Most investors are familiar with GW Pharmaceuticals plc (NASDAQ: GWPH) and its Sativex® cannabinoid medicine for the treatment of multiple sclerosis symptoms and cancer pain indications, but OWC Pharmaceutical Research Corp. (OTCQB: OWCP) is a lesser known company operating in the burgeoning industry.

Based in Israel, an international tech and biotech hub, and the epicenter of medical cannabis research, the OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines. The team is also working on several proprietary drug delivery mechanisms designed to provide consistent and reliable cannabinoid doses to patients more efficiently than smoking or consuming marijuana edibles.

Full Article below Please watch the interview: http://www.baystreet.ca/viewarticle.aspx?id=437873

99% of all CANNABIS RESEARCH IS BEING DONE IN ISREAL, OWCP IS AT THE EPICENTER OF THIS WORK


!!OWCP named one of top 20 Cannabis Stocks by Cannabis Investor Magazine!!

Cannabis Investor Magazine June Top 20 Cannabis Stocks

OWCP made the list huge recognition we are sitting on a goldmine.

https://finance.yahoo.com/news/cannabis-investor-magazine-june-top-130000276.htm

http://www.owcpharma.com/

[malagueule]

Cheeky Member Level Thursday, 09/29/16 04:35:07 PM
Re: Toxic Avenger post# 29176
Post #
29178
of 29192 Go
Deal with Ascendiant? Where is the deal, what is the deal, what are the terms, where are the terms, when did it close?

As for Wellington Shield's here's the Agreement and Terms STRAIGHT FROM THE FILINGS >>>

On May 12, 2016 the Company entered into three agreements with Wellington Shields and Co, LLC, the Company’s new investment banker.

In the first agreement, the Company engaged and retained Wellington Shields as its financial advisor as it relates to a private placement of up to $1,000,000, terminating at the close of business October 31, 2016. In consideration for the services rendered by Wellington Shields the Company agrees to pay a placement success fee equal to 10% of the gross proceeds and a warrant to purchase common shares of the Company equal to 4% of the amount of the placement at a purchase price equal to 110% of the implied price per share of the placement.

In the second agreement the Company engaged and retained Wellington Shields as a placement agent to Rx Safes, Inc as it relates to acquisition financing of up to $15,000,000, terminating at the close of business December 1, 2016. In consideration for the services rendered by Wellington Shields, the Company agrees to pay placement success fee equal to 8% of the gross proceeds of the placement, common shares equal to 3% of the outstanding shares of Rx Safes, Inc. post closing and a monthly accruing retainer of $10,000 per month, payable at the time of a financing at any amount of $5 million.

In the third agreement the Company engaged and retained Wellington Shields as its Exclusive Investment Banker for a twelve-month term as it relates to a Public Offering of up to $40,000,000 on a national exchange. In consideration for the services rendered by Wellington Shields the Company agrees to pay offering commission equal to 6% of the gross proceeds of the sale of the Company’s shares and offering warrants equal to 3% of the amounts raised at a purchase price equal to 110% of the implied price per share of the sale or 110% of the public market closing price of the Company’s common stock on the date of the sale, whichever is lower

[malagueule]

$GNID Alerted @ 0.10

Thanks to Cheeky for DD

**Easy Money, Must Read**

Guaranteed Nasdaq Up List Before Year's End, that's $4.00 minimum

How?

Wellington Shield's is underwriting a $40,000,000 CMPO Offering

A CMPO Offering does not require a Reverse Split.

Blue Chip Investment Banker Wellington Shield's and GNID agreed to remove debt utilizing non toxic financing of up to $1,000,000, plus set aside a $15,000,000 facility to acquire multiple companies with Revenues/Profits and EBITDA. This will change the Enterprise Value of GNID to approx. $25,000,000 and Wellington Shield's will then utilize their professional analyst to evaluate GNID and issue a NEW PPS. (Total Agreement valued @ $56,000,000, ALL Agreements in Q1)

No S-1 required, No Reverse Split required

A CMPO can be accomplished in 3 days with no one knowing when, go to bed at $0.50 or what ever it closes at and wake up the day of the CMPO at a minimum of $4.00 on the NASDAQ with HUGE Wallstreet backing.

All IN PLACE by END of Q3

Current Float Approx. 3,000,000 with total Outstanding approx. 16,000,000 and 85-90% RESTRICTED.

The best part is there's approx. 2,000,000 Shares Short. Remember what happened to KBIO, this is much bigger.

So look for Multiple 8-Ks confirming the Toxic Debt paid in full and Multiple Acquisitions ALL before the End of Q3.

From today's PPS you are looking at 20,000% to $4.00 but GNID will most likely trade at or above $10 when the CMPO goes through.

So $40,000,000 CMPO minus $15m Facility = $25m - $1m Debt Removal = $24m CASH ON HAND PLUS Multiple Revenue Stream from the Newly Acquired Companies.

Huge Christmas for Real Investors, TIMES RUNNING OUT

[malagueule]

MHYS Chart

[malagueule]

$MHYS alert!! CEO update!
Must see #bus657 #daughterofgod #Lionsgate pic.twitter.com/w77DQqY9d3

— doebop (@doebop) October 31, 2014

[malagueule]

MHYS - Multy-bagger

Should run hard here until Nov 17th. Where new O/S comes into effect. (not entirely sure they will be issued.) However New shares due to financing deal do not come into play until July 30th.

I see them issuing only if they come across a new big name project & need financing. (Assuming no revenues from existing projects)

Filed 8K
Link: http://biz.yahoo.com/e/141031/mhys8-k.html

as stated by LongInvestor

Two very good things from this financing deal.

1) The 8% Convertible note is not exercisable till 30 July 2015. The shares cannot be traded till 180 days after that date. So none of those shares can be sold before the end of next year.

2) The warrants that were issued cannot be exercised till the 5th (fifth) anniversary of the date they were issued! ( Will any of you still be here by then?)

Its all there folks - see for yourselves.

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10275242

CEO Grodnik answered shareholder questions about profit on finance deals on upcoming movie projects.

Thanks to doebop for info
Link here: ps://twitter.com/doebop/status/528271904382406656

In my opinion this is going to be a fun ride here. Going to buy more this week. Remember to take profits on the way up & if you can, play with free shares.

[AgSEC]

$BRGO. That's one of my babies. Biggest bull in the market.

[markpatrick23]

$BRGO$ be nauseous later or invert every dime now! Easy $$$ don't miss out

[Big_Money_Upward]

GLEC warming up! +15% today, +???% tomorrow!

[malagueule]

Bad Boy Vodka® DD

Here is a compilation of what i could find so far.( ongoing process to be updated )

November 2012 Andreas Johansson of AB Partners LLC approached Denis Rodman they made a deal to create Bad Boy Vodka®. Fast forwarding a few months, Premier Brands® come into the picture to help engineer the sales strategy & concept of the bottle.

July 10th - Premier Brands, Inc. Sends out a few e-mails to reps in the industry & some media contacts in hopes to broker a deal for the launch of Dennis Rodman's Bad Boy Vodka®. http://ih.advfn.com/p.php?pid=nmona&article=58362196 In the following hour the story was pick-up buy a reputable news agency's USA Today & around the globe shortly after.
- USA Today: http://ftw.usatoday.com/2013/07/dennis-rodman-vodka/
- Wall Street Journal: http://online.wsj.com/article/PR-CO-20130723-906771.html
- There are literally thousands...not gonna list all. My take is that they were totally unprepared for the frenzy of offers & inquiries that followed. http://www.brooklandsradio.co.uk/podcasts/BadboyVodka2013-07-24.mp3

Bad Boy Vodka will be exclusively sold and distributed through Premier Brands distribution channels, starting in California on July 27th. for AB Partners LLC. Having listened to the webinar & reading tweets for 2 weeks there appears to be interest from Alaska to the Philippines. Clearly they have to turn all this media into sales & stick to there marketing plan so that they are not pulled into 20 different directions. Here are a few pics of there warehouse they are using in UTAH for another one of there products.





Premier Brands President & CEO, Jorge Olson, has stated: there are no problems with production, put your order in and they will fill it, on the distributor's CC. Very big statement to make considering he's consulted names like Monster Energy Drinks, Rock Star to name a few. I would love to get my hands on a bottle next week, Let's be realistic, that ain't gonna happen. I have no doubt that Bad Boy Vodka® will sell, very well, but it will take time to get to everyone.

Currently I cannot find any commercials, or product placement for this product which is in a very early stages of launch, ( it's today d'uh ). Will post as soon as i find some.

BRND

[malagueule]

Premier Brands Property : Make Me® Vitamins




-Based In San Diego California, Founded in 2012.
-Product sold to several distributors and retailers in 5 states.
-Sold 15,000 sticks in the first 3 months. ( retail 0.99$ per stick ) as part of first retail test.
-Breaking the untapped Convenience store market with multi-vitamin powder sticks.
http://www.makemedrinks.com/
-over 20,000+ followers on twitter https://twitter.com/MakeMeDrinks/





Commercials:

Product sold at multiple retailers like:

over 7000 National stores as of June 18th 2012

Great NEWS

"Make ME" got today approved by Walgreens. 7000 Stores Nationwide! A great start for sales!

More to come...

— Make Me Drinks (@MakeMeDrinks) June 19, 2012

BRND

[malagueule]

Premier brands Property: ZizZazz

-Zizzazz® name brand of products that includes Zizzazz Energy Powder, Zizzazz Extreme Fitness Formula and KidZazz kids vitamins.
http://premierbrandsinc.com/investors/
http://zizzazz.com/

Commercials can be seen here:

Products sold here:

[malagueule]

PROJECTED/ACTUAL FINANCIALS FROM NTEK:
(Revenues & Expenses per OTC-Filing)


Q1 Projected $187k
Q1 ACTUAL $257K
~40% over projected


Q2 Projected $740k
Q2 (through 6/14) $800k
~8% over projected with 16 calendar days remaining.


@ current rate ($800k / 74 days) = $10,810.-/day

x 16 days = ~$173,000.00,... plus $60,000.00 (over proj)
is ~$233,000.00 OVER PROJECTED, or >31%

$800k + $173k = $973k Gross Revenues for Q2


+ $257k for Q1 & NTEK will have generated ~$1.2mm in its FIRST
2 Q's since emerging from R&D (retired 238mm shares, with 68mm
more targeted w/in 90days, & has said to be on pace for Q3 & Q4
Revenue Projections!!)


HERE, from the FILINGS!! Projected REVENUES & EXPENSES!!!!



http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=97415

[malagueule]

Nanoteck Entertainment Property

"WineChannel TV" http://investorshub.advfn.com/boards/read_msg.aspx?message_id=90379053

Jumper™!! http://investorshub.advfn.com/boards/read_msg.aspx?message_id=90376846

"On the Mike" http://investorshub.advfn.com/boards/read_msg.aspx?message_id=90376174

Foresite's "Compliance TV Channel" http://investorshub.advfn.com/boards/read_msg.aspx?message_id=90375300

NanoTweet & NanoTweet Scheduler 1.0.1 http://investorshub.advfn.com/boards/read_msg.aspx?message_id=90371959

MultiPin™ PinBall Machine http://investorshub.advfn.com/boards/read_msg.aspx?message_id=90369137

Total 4K Package Solutions (COMING SOON) http://investorshub.advfn.com/boards/read_msg.aspx?message_id=90365980

"MMA DAY TV" http://investorshub.advfn.com/boards/read_msg.aspx?message_id=90363969

"Digital Fish Tanks" http://investorshub.advfn.com/boards/read_msg.aspx?message_id=90352141

VODwiz™ (Coming Soon) http://investorshub.advfn.com/boards/read_msg.aspx?message_id=90249930

[malagueule]

Nanoteck Entertainment & IPTV Lesson #1

Roku has had IPTV for years now. I do not have cable and will never go back. The amount of content available is astounding. Not only are there hundreds of FREE channels but you also have subscription services like Netflix and Hulu which many of you are probably familair with. HOWEVER, among these 2 I also use Amazon to rent, purchase and watch any movie and or TV show. Here are the subscriptions and what you can expect to pay.

1. Netflix- 7.99/ month
2. Hulu Plus 7.99/ month
3. Amazon Prime - ONLY $79/ per YEAR! less than Netflix and Hulu. Plus they have thousands of titles to chose from. If you want to look at Amazon's collection please just go to their ON Demand section and have a look. If there is a television show you like and you cannot find it on NetFlix or Amazon you can actually rent Episodes for only 99 Cents. You also have the option to purchase the entire season if you wish.

When you break all of this down you would only pay $22.56 a month for more selections than a cable provider ever dreamed of giving me. Seems like a no brain-er these days with people trying to save money.

NOW
Let's talk about Amazon. Because some people DO NOT KNOW ABOUT IT. There has never been anything I cannot find to watch. Some content I may have to pay for rental but if you look at the big picture you are STILL saving money.
ALSO, You have a choice to view your Rentals in Standard or High Definition. Amazon is the leader IMO. They have the rights to almost everything. Even out of print titles. So, I think it's safe to say these guys will be the VERY FIRST to have Ultra High Def Rentals. For those who do not know, many movies have already been shot in 4k. ALSO, there are more and more 4k Mastered movies popping up everywhere. Right now Sony is the leader. Amazon SELLS all Sony titles either for rent or purchase. If you purchase a title you can actually downloaded it on your hard drive or other storage device and virtually watch it on ANY device with a USB port or SD card slot. And what does the Nuvola have? BOTH! So, I think it is safe to say not only with the Nuvola you have IPTV but you can watch your personal movie collection.

Right now I have my own personal movie collection of about 500 titles on a small external hard drive. To view my collection I had to buy another device besides my Roku. This device plays my personal library. (More to come on that).

Will the Nuvola eliminate my need for 2 devices? If I had to bet on it I would bet a million shares this player does it all!

Below I have some screen shots of Amazon and how it works. I also have some of the Titles that have already either been SHOT in 4k or Mastered in 4K and will be available.

My PREDICTION!
With the Nuvola I will be able to go to Amazon and watch ANY 4k Movie available in the near future. Why do I think this? Well when I search for movies on AMAZON in 4K look what pops up ALREADY!!





That is my prediction. Remember 4K content will only work if you have a 4K set. I will be purchasing NTEK's 50" when it's available for only $1499 + the Nuvola for $299. Grand total for "THE WORKS" $1798..As opposed to SONY's Ultra HD TV for $5000?? haha. And their box for $699? Which ONLY Plays SONY movies?? I don't think so!! LOL!

What I'm trying to get to here is the Nuvola set top box has all the channels you need to watch 4k Content when it is available. I also predict these titles will become available on Amazon FIRST. (I've shown you why) No matter who makes or distributes the TV shows or Movies IN 4K (Netflix, Hulu, AMAZON, etc you will be able to watch whatever you want with the NUVOLA.

I hope everyone followed that. What it boils down to is this is ONLY the beginning of 4k content and it will explode. There is NO need to worry about not having anything to watch.

Here is what my Amazon prime account looks like. I may watch movies for free in HD with my prime subscription or if the title isn't available for prime I may rent or purchase it. (See Pics). My prediction is there will be another option (as shown in the picture) for 4k Viewing. (I used Photoshop to put the 4K option there but you get the idea). As you see with my Amazon Prime subscription I already watch thousands of titles for free. See the green button???

3.99 / 48 hours for standard
4.99-5.99 / 48 hours for High Def
5.99-7.99 / 48 hours FOR ULTRA HIGH DEFINITION!!!



Here is my prediction what Amazon will OFFER when 4K hits the streets. The option is circled in RED



I went though Amazon and found ALL the movies on their site that said filmed in 4K or Mastered in 4K..
HERE THEY ARE!!!











ANY QUESTIONS?